促红细胞生成素治疗慢性心力衰竭的疗效观察

Curative effect observation on erythropoietin in treating chronic heart failure

目的 观察在慢性心衰标准治疗的基础上加用促红细胞生成素（EPO）皮下注射的临床疗效及预后.方法 选择60例慢性心衰患者,随机分为2组,对照组（常规治疗组）29例服用β受体阻滞剂＋血管紧张素转化酶抑制剂（ACEI）或血管紧张素受体拮抗剂（ARB）＋利尿剂,症状严重时加用强心药.治疗组31例在对照组的基础上皮下注射EPO 100 lU/kg,每周1次,疗程6个月.治疗前后采用超声心动图及血常规进行疗效观察 并统计两组治疗后症状改善率、再住院率、死亡率.结果 EPO治疗组与对照组比较,治疗后两组左室射血分数（LVEF）及血红蛋白（HB）浓度均有所提高,左室舒张末期内径（LVEDD）、左室收缩期末内径（LVESD）均有缩小,但EPO组明显,与对照组比较,有统计学差异 治疗后与治疗前比较,EPO组症状改善率、心衰再住院率、死亡率下降更明显,两组比较有统计学差异.结论 促红细胞生成素能改善慢性心衰患者的心功能、并使心衰住院率、死亡率进一步下降,长期使用安全有效,值得临床研究应用.

Objective To observe the clinical curative effect and prognosis of chronic heart failure standard therapy combined with erythropoietin （EPO） subcutaneous injection. Methods 60 patients with chronic heart failure were se lected, and randomly divided into the treatment group and the control group （conventional） 29 patients taking beta blockers ＋ angiotensin 1-converting enzyme inhibitors （ACEI） or angiotensin receptor blockers （arbs） ＋ diuretics, a serious symptoms of heart. 31 cases in treatment group were injected by 1001U/kg epithelial EPO, 1 time each week, treatment for six months. Echocardiography and routine blood were carried out for clinical observation before and after the treatment and mark the hospitalization period symptoms and mortality rates. Resulta After treatment, the left ventricular ejection fraction （LVEF） and hemoglobin （HB） concentrations were all improved, and left ventricular end-diastolic diameter （LVEDD） and left ventricular shrink diameter LVESD （final） were all narrow, but EPO group, compared with controls, showed significant difference on the symptoms period, mortality rates.Conclusion It shows thaterythropoietin can improve cardiac function in patients with chronic heart failure, and reduce the heart rate and mortality, and it＇s safe and effective for long-term use, clinical application research should be carried out.